Articles from Adimab, LLC

Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that five therapeutic products containing molecules discovered or optimized by Adimab have been approved for commercial sale. Adimab’s first partnered program to receive approval was Innovent’s TYVYT® (sintilimab injection), which is currently marketed by Innovent and Lilly in China for seven cancer indications.

Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that it entered into partnership agreements with 17 new companies in 2024. In addition, Adimab announced the expansion of eight of its current partnerships and the achievement of 51 technical and development milestones across numerous collaborations.

Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced the appointment of Aaron Sato, Ph.D., to the newly created position of Chief Strategy Officer. Dr. Sato will be responsible for guiding marketing strategies and engaging with potential partners across a variety of therapeutic approaches, including Adimab's technology related to monoclonal and multispecific antibody discovery and optimization, T-cell engagers, TCRs, GPCRs and other membrane-obligate targets, as well as other existing and new technology offerings. In addition, Dr. Sato will help lead internal cross-functional efforts to develop competitive intelligence, perform internal and external technology analysis, and drive external technical engagement with drug development companies, key opinion leaders, and industry leaders.

Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that it is nearing completion of the addition of more than 50,000 square feet to its headquarters and research campus in Lebanon, New Hampshire. Over the past seven years, Adimab has added more than 400 royalty bearing therapeutic programs. To accommodate this continual growth, Adimab has increased headcount by approximately 40% over the past three years.

Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that 12 new partner programs entered clinical development in 2023, including programs by Biotheus, Cullinan Oncology, IgM Biosciences, Inc., Invivyd, NextPoint, Sensei Biotherapeutics, Takeda, and Therini Bio. This brings the total number of Adimab partner programs that have entered the clinic to 74.

Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that it entered into partnership agreements with 10 new companies in 2023. In addition, Adimab announced the expansion of nine of its current partnerships and the achievement of 59 technical and development milestones across numerous collaborations.

Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and multispecific antibodies, announced today that Adimab and LinkedUp Bioscience, Inc. (and related parties) have agreed to resolve litigation in which Adimab alleged, among other things, the misappropriation of trade secrets and in which the LinkedUp parties made certain counterclaims including unfair and deceptive trade practices, intentional interference with business relationships, and infliction of emotional distress. The agreement provides that the litigation will be dismissed with prejudice. None of the parties admit any liability or wrongdoing. In return for undisclosed consideration to Adimab, Adimab has withdrawn its claims that the LinkedUp parties misappropriated Adimab technology or breached any confidentiality agreement, and the LinkedUp parties shall have the unfettered right to continue using their technology as it exists today. Similarly, LinkedUp and its related parties have withdrawn their counterclaims, including unfair and deceptive trade practices, intentional interference with business relationships, and infliction of emotional distress. The remaining terms of the agreement remain confidential.

Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that seven new partner programs entered clinical development in 2022, including programs by Biotheus, Dragonfly, Innovent, Surface Oncology, and a program with financial support from the Gates Foundation. This brings the total number of Adimab partner programs that have entered the clinic to 62.

Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that it entered into partnership agreements with 11 new companies in 2022. In addition, Adimab announced the expansion of nine of its current partnerships and the achievement of 52 technical and development milestones across numerous collaborations.

Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced the appointments of Philip T. Chase as Chief Executive Officer and Eric M. Krauland as President and Chief Scientific Officer. Mr. Chase has been serving as Adimab’s General Counsel for more than ten years and Dr. Krauland has held a variety of leadership positions at Adimab since 2007, including serving as Adimab’s Chief Scientific Officer since 2017. After 15 years, former CEO and Co-Founder Tillman U. Gerngross will step away from day-to-day operations at Adimab and move to a strategic role as Executive Chairman of the Board.

Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced an expanded offering of proprietary technologies to aid the development of antibody and multispecific therapeutic modalities. These technologies are a result of a collaborative effort between Adimab’s Computational Biology team in Palo Alto, CA and Antibody Engineering team in Lebanon, NH to provide Adimab’s partners with end-to-end solutions for therapeutic antibodies across multiple formats.

Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that in 2021 it entered into agreements with 13 new companies. In addition, Adimab announced the expansion of 14 of its current partnerships and the achievement of 52 technical and development milestones across numerous collaborations.